肝细胞癌转化和新辅助治疗的进展与挑战

Advances and challenges of conversion therapy and neoadjuvant therapy in hepatocellular carcinoma

肝细胞癌(以下简称肝癌)存在可切除率低、复发率高的痛点。转化和新辅助治疗是改善肝癌患者长期预后的有效策略。随着临床新技术、新方法应用以及不断涌现的新型抗肿瘤药物,肝癌转化和新辅助治疗迎来高速发展,但同时也面临诸多新挑战。笔者结合自身临床经验以及该领域的最新进展,探讨肝癌转化和新辅助治疗策略以及面临的挑战。

Hepatocellular carcinoma(HCC)is characterized by a low resection rate and a high postoperative recurrence rate.Conversion therapy and neoadjuvant therapy are effective stra-tegies to improve the long-term prognosis of patients with HCC.With the clinical application of new technologies and methods and the continuous emergence of new anti-tumor drugs,the conversion therapy and neoadjuvant therapy of HCC have ushered in an unprecedented development.At the same time,they are also facing many new challenges.Based on our own clinical experience and the latest progress in conversion therapy and neoadjuvant therapy of HCC,the authors classify and summarize the selection of treatment strategies and the challenges faced in HCC conversion therapy and neoadjuvant therapy.